Conversely, while WHO-HAEM5 requires at least 20% blasts to define AML in the absence of an AML-defining genetic lesion, the ICC recognizes an “MDS/AML” overlap group encompassing cases with 10–19% blasts that lack AML-defining genetics, effectively replacing MDS-EB2. This evidence concerns the gene MAPRE2 and myelodysplastic syndrome.